GHRP-6 vs Hexarelin

Hexarelin, by a meaningful margin. Hexarelin produces the largest acute GH pulse of any GHRP at equivalent doses - larger than GHRP-6, GHRP-2, or ipamorelin. That advantage shrinks over a cycle because of hexarelin's well-documented desensitization (40-50% reductions in GH response after 8-12 weeks), while GHRP-6's response curve declines more gradually. For a single injection, hexarelin wins. For a sustained protocol, the advantage narrows considerably.

There is animal research showing cardioprotective effects through CD36 receptor activation, independent of hexarelin's GH-releasing action. In cardiac injury models (ischemia-reperfusion), hexarelin reduces cardiomyocyte damage through this separate pathway. GHRP-6 does not share the CD36 activity. The cardioprotective signature is genuinely interesting and has kept hexarelin in research literature, but it has not advanced to human cardiac trials. Treating it as a clinical cardiac intervention would be premature.

Probably yes. The February 2026 FDA reclassification review includes BPC-157, CJC-1295, ipamorelin, and several others, but GHRP-6 and hexarelin are generally expected to remain on Category 2 permanently. Both have side effect profiles (cortisol and prolactin elevation, appetite effects, desensitization) that are harder to defend compared to newer alternatives like ipamorelin. This is not a formal FDA position, but it is the broad expectation among people tracking peptide regulation.

GHRP-6 has the more dramatic appetite side effect - users describe intense hunger within 15-30 minutes of injection, which makes it difficult to use for body composition goals. Hexarelin has more cortisol and prolactin elevation and worse desensitization kinetics but does not hit appetite as hard. On balance, neither is clean. Ipamorelin exists specifically because both of these compounds were uncomfortable enough that people wanted a better option. If side effects are the deciding factor, the correct answer is neither.

GHRP-6 works via First-generation growth hormone secretagogue that stimulates GH release and increases appetite via. Hexarelin works via Potent growth hormone secretagogue with cardioprotective properties beyond GH stimulation. They differ in FDA approval status, efficacy data, and cost.

GHRP-6 typically costs $35 - $70/mo, while Hexarelin costs $40 - $80/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

GHRP-6 is not FDA-approved (Not submitted). Hexarelin is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of GHRP-6 include Significant increase in appetite, Water retention, Tingling or numbness. Common side effects of Hexarelin include Increased appetite, Cortisol elevation, Prolactin elevation. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.